NeoGenomics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
NeoGenomics, Inc. (NEO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -3.29% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2022-02-25
- NeoGenomics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -3.29%.
- NeoGenomics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -1.41%, a 119.03% decline from fiscal 2019.
- NeoGenomics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was 7.41%, a 95.00% increase from fiscal 2018.
- NeoGenomics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2018 was 3.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2021-12-31 | -3.29% 10-K · filed 2022-02-25 | |
| 2020-12-31 | -1.41% 10-K · filed 2022-02-25 | -1.42% 10-K · filed 2021-02-25 |
| 2019-12-31 | 7.41% 10-K · filed 2022-02-25 | 7.49% 10-K · filed 2020-02-28 |
| 2018-12-31 | 3.80% 10-K · filed 2021-02-25 | |
| 2017-12-31 | -17.57% 10-K · filed 2020-02-28 | -13.38% 10-K · filed 2018-03-13 |
| 2016-12-31 | -1.88% 10-K · filed 2019-02-26 | |
| 2015-12-31 | -29.17% 10-K · filed 2018-03-13 | |
| 2014-12-31 | 5.89% 10-K · filed 2017-03-14 | |
| 2013-12-31 | 1.89% 10-K · filed 2016-04-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |